Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04644 |
PDGFB Protein, Human, Recombinant (His)
platelet-derived growth factor beta polypeptide,SSV... |
Human | P. pastoris (Yeast) |
Platelet-derived growth factor-B (PDGFB) is necessary for normal cardiovascular development. The administration of PDGFB alone normalized tumor vasculature by increasing periendothelial coverage and vascular functionality. Interestingly, this effect exerted by PDGFB was also observed in the presence of DAPT. So PDGFB is able to improve tumor vascularity and allows the anticancer action of DAPT in the tumor. PDGFB Protein, Human, Recombinant (His) is expressed in yeast with His tag. The predicted... | |||
TMPY-04214 |
CCL5 Protein, Human, Recombinant
SISd,TCP228,chemokine (C... |
Human | E. coli |
CCL5 Protein, Human, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 8 kDa and the accession number is D0EI67. | |||
TMPY-01072 |
CCL5 Protein, Human, Recombinant (His & mucin)
D17S136E,SCYA5,SIS-δ,SISd,SIS... |
Human | HEK293 Cells |
CCL5 Protein, Human, Recombinant (His & mucin) is expressed in HEK293 mammalian cells with His and mucin tag. The predicted molecular weight is 34 kDa and the accession number is D0EI67. | |||
TMPJ-00993 |
CCL5 Protein, Rat, Recombinant (E. coli, His)
Small-inducible cytokine A5,SIS-δ... |
Rat | E. coli |
C-C motif chemokine 5(CCL5) is a β-chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes. CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5. Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28. Oligomerization of CCL5 on glycosaminoglycans is required for CCR1mediated leu... | |||
TMPH-02567 |
CCL4 Protein, Mouse, Recombinant (His)
Immune activation protein 2,SIS-gamma,Mip1... |
Mouse | E. coli |
Monokine with inflammatory and chemokinetic properties. | |||
TMPJ-00005 |
CCL3 Protein, Human, Recombinant
MIP-1-Alpha,CCL3,MIP-1-α,Small-Induc |
Human | E. coli |
Human Chemokine (C-C Motif) Ligand 3 (CCL3) is a small cytokine belonging to the CC chemokine family. CCL3 is primarily expressed in T cells, B cells, and monocytes after antigen or mitogen stimulation. CCL3 exhibits chemoattractive and adhesive effects on lymphocytes. CCL3 exerts multiple effects on hematopoietic precursor cells and inhibits the proliferation of hematopoietic stem cells in vitro as well as in vivo. CCR1 and CCR5 have been identified as functional receptors for CCL3. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |